Literature DB >> 21253857

Evaluation of osteoclastogenesis via NFκB decoy/mannosylated cationic liposome-mediated inhibition of pro-inflammatory cytokine production from primary cultured macrophages.

Thuy Duong Dinh1, Yuriko Higuchi, Shigeru Kawakami, Fumiyoshi Yamashita, Mitsuru Hashida.   

Abstract

PURPOSE: To explore the effect of NFκB activation in macrophages on osteoclastogenesis of bone marrow cells for potential application as a new type of therapy for preventing bone loss.
METHODS: Primary cultured macrophages and bone marrow cells were prepared from mice. As macrophage-targeted carriers, Mannosylated cationic liposomes (Man-liposomes) were prepared and were allowed to form complexes with NFκB decoy (a double-stranded oligonucleotide). Cellular uptake, inhibition of NFκB activation, and cytokine production were evaluated using macrophages. Osteoclastogenesis was investigated using bone marrow cells, which were cultured in the conditioned medium prepared from macrophages with or without Man-liposome/NFκB decoy complexes treatment.
RESULTS: Cellular accumulation of NFκB decoy was enhanced by Man-liposome. NFκB activation in macrophages and TNF-α production were suppressed in macrophages by Man-liposome/NFκB decoy complexes but not by the naked NFκB decoy, Gal-liposome/NFκB decoy complexes, or Man-liposome/random decoy complexes. Osteoclastogenesis of bone marrow cells was induced in the conditioned medium prepared from activated macrophages but not by activated macrophages treated with Man-liposome/NFκB decoy complexes.
CONCLUSION: Osteoclastogenesis induced by activated macrophages could be suppressed by the treatment macrophages with Man-liposome/NFκB decoy complexes. Macrophage-targeted delivery of NFκB decoys using Man-liposomes may be promising in its use for the remediation of bone loss.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21253857     DOI: 10.1007/s11095-011-0366-0

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  35 in total

Review 1.  Chemical modification of siRNAs for in vivo use.

Authors:  Mark A Behlke
Journal:  Oligonucleotides       Date:  2008-12

2.  In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction.

Authors:  R Morishita; T Sugimoto; M Aoki; I Kida; N Tomita; A Moriguchi; K Maeda; Y Sawa; Y Kaneda; J Higaki; T Ogihara
Journal:  Nat Med       Date:  1997-08       Impact factor: 53.440

Review 3.  In vivo studies with antisense oligonucleotides.

Authors:  S Akhtar; S Agrawal
Journal:  Trends Pharmacol Sci       Date:  1997-01       Impact factor: 14.819

4.  Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis.

Authors:  Y Abu-Amer; J Erdmann; L Alexopoulou; G Kollias; F P Ross; S L Teitelbaum
Journal:  J Biol Chem       Date:  2000-09-01       Impact factor: 5.157

5.  Activation of human B cells by phosphorothioate oligodeoxynucleotides.

Authors:  H Liang; Y Nishioka; C F Reich; D S Pisetsky; P E Lipsky
Journal:  J Clin Invest       Date:  1996-09-01       Impact factor: 14.808

6.  Therapeutic effect of in vivo transfection of transcription factor decoy to NF-kappaB on septic lung in mice.

Authors:  Naoyuki Matsuda; Yuichi Hattori; Yoshika Takahashi; Jun Nishihira; Subrina Jesmin; Masanobu Kobayashi; Satoshi Gando
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2004-08-06       Impact factor: 5.464

Review 7.  Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis.

Authors:  Peter C Taylor; Marc Feldmann
Journal:  Nat Rev Rheumatol       Date:  2009-10       Impact factor: 20.543

8.  Effect of different chemically modified oligodeoxynucleotides on immune stimulation.

Authors:  Q Zhao; J Temsamani; P L Iadarola; Z Jiang; S Agrawal
Journal:  Biochem Pharmacol       Date:  1996-01-26       Impact factor: 5.858

9.  Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis.

Authors:  J Keffer; L Probert; H Cazlaris; S Georgopoulos; E Kaslaris; D Kioussis; G Kollias
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

Review 10.  Osteoclasts; culprits in inflammatory osteolysis.

Authors:  Steven L Teitelbaum
Journal:  Arthritis Res Ther       Date:  2005-11-29       Impact factor: 5.156

View more
  4 in total

1.  NF-κB decoy oligodeoxynucleotide inhibits wear particle-induced inflammation in a murine calvarial model.

Authors:  Taishi Sato; Jukka Pajarinen; Tzu-hua Lin; Yasunobu Tamaki; Florence Loi; Kensuke Egashira; Zhenyu Yao; Stuart B Goodman
Journal:  J Biomed Mater Res A       Date:  2015-07-14       Impact factor: 4.396

2.  Suppression of wear-particle-induced pro-inflammatory cytokine and chemokine production in macrophages via NF-κB decoy oligodeoxynucleotide: a preliminary report.

Authors:  Tzu-Hua Lin; Zhenyu Yao; Taishi Sato; Michael Keeney; Chenguang Li; Jukka Pajarinen; Fan Yang; Kensuke Egashira; Stuart B Goodman
Journal:  Acta Biomater       Date:  2014-05-09       Impact factor: 8.947

Review 3.  Chronic inflammation in biomaterial-induced periprosthetic osteolysis: NF-κB as a therapeutic target.

Authors:  Tzu-hua Lin; Yasunobu Tamaki; Jukka Pajarinen; Heather A Waters; Deanna K Woo; Zhenyu Yao; Stuart B Goodman
Journal:  Acta Biomater       Date:  2013-10-01       Impact factor: 8.947

Review 4.  Novel biological strategies for treatment of wear particle-induced periprosthetic osteolysis of orthopaedic implants for joint replacement.

Authors:  S B Goodman; E Gibon; J Pajarinen; T-H Lin; M Keeney; P-G Ren; C Nich; Z Yao; K Egashira; F Yang; Y T Konttinen
Journal:  J R Soc Interface       Date:  2014-01-29       Impact factor: 4.118

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.